Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the ...

Washington based renowned think-tank Wilson Centre has made a startling disclosure about the banned Baloch Liberation Army (BLA) exploiting women for carrying out terrorist activities in ...

Larimar Therapeutics, Inc. (NASDAQ:LRMR), with a market capitalization of $228 million, is a clinical-stage biopharmaceutical ...

Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click ...

Explore the case of Joanne Chesimard, also known as Assata Shakur, a controversial figure convicted of killing a New Jersey ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

MeiraGTx's financials show $125 million in cash, but additional funding will be needed within the next 12 months. Click for ...

The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.